NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BIAF

BioAffinity Technologies Inc

Jul 03 • 04:00PM ET

0.2724

Dollar change -0.0176
Percentage change -6.07	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: CDXS AVDX BNGO CRSP EDIT NTLA SGMO BLUE GILD VRTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.72	Insider Own	28.84%	Shs Outstand	28.46M	Perf Week	-24.31%
Market Cap	7.75M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	0.00%	Shs Float	20.25M	Perf Month	-3.61%
Enterprise Value	8.64M	PEG	-	EPS next Q	-0.10	Inst Own	1.80%	Short Float	3.80%	Perf Quarter	-69.39%
Income	-9.74M	P/S	0.88	EPS this Y	46.67%	Inst Trans	167.27%	Short Ratio	0.11	Perf Half Y	-70.71%
Sales	8.81M	P/B	3.45	EPS next Y	55.00%	ROA	-143.25%	Short Interest	0.77M	Perf YTD	-70.07%
Book/sh	0.08	P/C	17.61	EPS next 5Y	-	ROE	-290.85%	52W High	2.99 -90.89%	Perf Year	-87.73%
Cash/sh	0.02	P/FCF	-	EPS past 3/5Y	4.55% -10.71%	ROIC	-456.80%	52W Low	0.16 66.20%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	27.48%	Volatility	24.10% 15.07%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.98	EPS Y/Y TTM	22.41%	Oper. Margin	-109.38%	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	78.40%	Profit Margin	-110.55%	RSI (14)	48.04	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.55	EPS Q/Q	17.29%	SMA20	-1.58%	Beta	2.52	Target Price	6.00
Payout	-	Debt/Eq	0.92	Sales Q/Q	-22.97%	SMA50	-9.78%	Rel Volume	0.10	Prev Close	0.29
Employees	57	LT Debt/Eq	0.48	Earnings	May 15 BMO	SMA200	-67.69%	Avg Volume	6.95M	Price	0.27
IPO	Sep 01, 2022	Option/Short	No / No	EPS/Sales Surpr.	0.00% -12.11%	Trades		Volume	667,856	Change	-6.07%

Jul-01-25 09:33AM	The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies (Zacks) -8.25%
Jun-30-25 04:41PM	Top Research Reports for Meta Platforms, ServiceNow & Booking (Zacks)
Jun-26-25 09:00AM	bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference (Business Wire) +46.90%
Jun-24-25 09:00AM	bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy (Business Wire) +7.73%
Jun-11-25 09:00AM	bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas Leadership Board (Business Wire)
09:00AM	Loading…
Jun-03-25 09:00AM	bioAffinity Technologies Works With Cardinal Health OptiFreight® Logistics to Help Meet Demand for CyPath® Lung (Business Wire) +7.58%
May-29-25 02:34PM	BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors (Insider Monkey) -15.83%
May-28-25 09:00AM	bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics (Business Wire) +46.84%
May-20-25 12:15PM	BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline (Zacks) +29.79%
09:00AM	bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer (Business Wire)
May-15-25 08:30AM	bioAffinity Technologies Reports First Quarter 2025 Results (Business Wire) -8.62%
May-08-25 09:00AM	Independent White Paper Highlights Real-World Impact of bioAffinity Technologies CyPath® Lung in Diagnosing Early-Stage Lung Cancer (Business Wire) -5.31%
May-07-25 01:15PM	WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering (PR Newswire)
01:00PM	bioAffinity Technologies Announces Closing of $3.25 Million Offering (Business Wire)
10:40AM	BioAffinity Technologies announces pricing of $3.25M offering (TipRanks)
10:30AM	Loading…
May-06-25 10:30AM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering (PR Newswire) -44.50%
09:25AM	bioAffinity Technologies Announces Pricing of $3.25 Million Offering (Business Wire)
09:05AM	The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies (Zacks)
May-05-25 04:23PM	Top Stock Reports for Alphabet, Berkshire Hathaway & Visa (Zacks) -15.27%
Apr-17-25 09:15AM	bioAffinity Technologies Increases Efficiency of CyPath Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost (Business Wire) +9.67%
Apr-07-25 12:16PM	BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues (Zacks)
Mar-31-25 09:28AM	bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 (Business Wire)
Mar-26-25 09:00AM	Case Study: bioAffinity Technologies CyPath Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer (Business Wire)
Mar-19-25 09:00AM	Case Study: bioAffinity Technologies Positive CyPath Lung Result Leads to Detecting Breast Cancer Recurrence (Business Wire)
Mar-13-25 09:00AM	Physicians Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer (Business Wire) -13.73%
Mar-06-25 08:00AM	bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath Lung Sales Growth (Business Wire)
Feb-26-25 12:10PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million (PR Newswire) -11.08%
11:30AM	bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million (Business Wire)
Feb-25-25 11:05AM	WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million (PR Newswire) -16.67%
09:58AM	bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million (Business Wire)
08:00AM	Loading…
Jan-22-25 08:00AM	bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic (Business Wire)
Jan-13-25 08:00AM	bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath Lung (Business Wire) -6.83%
Jan-10-25 09:00AM	Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -12.06%
Dec-21-24 06:33AM	bioAffinity Technologies Boosts Sales with CyPath Lung (TipRanks)
Dec-17-24 08:00AM	Join bioAffinity Technologies Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 (Business Wire) +15.84%
Dec-12-24 08:00AM	bioAffinity Technologies Set for Continued Expansion in 2025 (Business Wire)
Dec-05-24 08:00AM	Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule (Business Wire)
Nov-14-24 08:00AM	bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 (Business Wire)
Nov-04-24 08:00AM	bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development (Business Wire)
Oct-30-24 08:00AM	bioAffinity Technologies Announces Award of Japanese Patent for CyPath Lung (Business Wire) +5.38%
Oct-21-24 11:39AM	WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement (PR Newswire)
10:45AM	bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement (Business Wire)
Oct-18-24 02:57PM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement (PR Newswire) -33.80%
12:45PM	bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement (Business Wire)
Oct-16-24 08:00AM	bioAffinitys CyPath Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines (Business Wire) +10.10%
Oct-10-24 08:00AM	bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer (Business Wire)
Oct-09-24 08:00AM	bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test (Business Wire) +13.71%
Sep-18-24 08:00AM	Peer-Reviewed Study: bioAffinity Technologies CyPath Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis (Business Wire)
Aug-23-24 05:15PM	bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO (Business Wire)
Aug-14-24 09:25AM	bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath Lung Sales (Business Wire)
Aug-05-24 02:00PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (PR Newswire)
01:17PM	bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (Business Wire)
Aug-02-24 10:00AM	WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (PR Newswire) -27.31%
09:25AM	bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (Business Wire)
Jul-12-24 09:35AM	Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jul-09-24 08:00AM	bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath Lung (Business Wire) +7.17%
Jul-05-24 09:00AM	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-12-24 08:00AM	bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath Lung Tests (Business Wire)
May-15-24 09:55PM	BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024 (InvestorPlace) +30.32%
09:15AM	bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath Lung Sales and Increased Laboratory Volumes (Business Wire)
May-02-24 08:00AM	bioAffinity Technologies News Update (Business Wire) -6.53%
Apr-24-24 08:00AM	bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth (Business Wire) -5.41%
Apr-09-24 08:00AM	bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening (Business Wire)
Apr-01-24 10:53PM	BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023 (InvestorPlace)
09:49AM	bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Mar-08-24 01:15PM	Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
12:45PM	bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Mar-06-24 10:45AM	WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) -50.00%
09:46AM	bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Mar-05-24 08:00AM	bioAffinity Technologies Reports Accelerating Sales Growth of CyPath Lung (Business Wire) +27.66%
Feb-21-24 08:00AM	bioAffinity Technologies News Update (Business Wire)
Feb-06-24 08:00AM	Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies Medical and Scientific Advisory Board and Incorporates CyPath Lung into Medical Practice (Business Wire)
Jan-30-24 08:00AM	bioAffinity Technologies In The News (Business Wire)
Jan-23-24 08:00AM	bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer (Business Wire)
Jan-08-24 08:00AM	bioAffinity Technologies In the News (Business Wire)
Jan-05-24 09:00AM	bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-05-23 08:00AM	bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors (Business Wire)
Nov-30-23 08:00AM	CMS Posts Final Payment Determination for bioAffinity Technologies CyPath Lung Effective January 2024 (Business Wire) +22.96%
Nov-28-23 08:00AM	bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post (Business Wire)
Nov-15-23 08:00AM	bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening (Business Wire)
Nov-14-23 04:01PM	bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-06-23 08:00AM	bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales (Business Wire)
Oct-10-23 08:00AM	bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -31.17%
Sep-19-23 08:00AM	bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services (Business Wire)
Sep-07-23 08:00AM	bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
Aug-14-23 05:03PM	bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-12-23 08:00AM	AMA Issues CPT Code for bioAffinity Technologies CyPath® Lung Test for Early-Stage Lung Cancer (Business Wire)
Jun-15-23 08:00AM	bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium (Business Wire)
May-22-23 08:00AM	bioAffinity Technologies Presents Research Findings at CYTO 2023 (Business Wire)
May-15-23 08:00AM	bioAffinity Technologies Reports First Quarter 2023 Financial Results (Business Wire)
May-01-23 08:00AM	bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer (Business Wire) +5.13%
Apr-25-23 08:00AM	bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium (Business Wire)
Apr-05-23 08:00AM	bioAffinity Technologies to Ring Nasdaq Closing Bell Today (Business Wire) +7.78%
Mar-31-23 05:52PM	bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire) +5.00% -13.23%
Mar-28-23 08:00AM	bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer (Business Wire)
Mar-24-23 08:00AM	bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 (Business Wire)
Feb-13-23 08:00AM	bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications (Business Wire)
Jan-24-23 08:00AM	bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research (Business Wire) +75.47%
Jan-04-23 08:00AM	bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments (Business Wire) +5.77%

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIAF

BioAffinity Technologies Inc

Upgrade your FINVIZ experience